Knowing that the broadly expressed PACE4 is overexpressed in prostate cancer cells, we previously evaluated the possibility that higher PACE4 levels in cancer cells could yield tumor specific accumulation of the peptide and in turn could benefit both therapeutic and tumor detection point of views. This evidence concerns the gene PCSK6 and Familial prostate cancer.